Insulin resistance, blood sugar regulation, metabolic syndrome, and body composition
461 articles
A 6-month AI-driven personalized diet intervention cut BMI by 33% and reduced biological age by 8 years in morbidly obese patients.
A sweeping review of GLP-1 agonists, tirzepatide, and emerging hormone combos reshaping obesity treatment in 2025.
The TRIUMPH program tests retatrutide across 5,800+ patients using a novel basket trial design to simultaneously tackle obesity and its complications.
A molecular-level deep dive into AGE formation kinetics, RAGE isoforms, downstream transcriptional networks, and evidence-based interventions — for those who want the full mechanistic picture.
Baxdrostat becomes the first-in-class aldosterone synthase inhibitor approved to treat resistant hypertension alongside existing drugs.
Go beyond the basics and explore the biochemical mechanisms behind glycation — from the Maillard reaction cascade to RAGE signaling and tissue cross-linking — to understand why AGEs are central to aging and metabolic disease.
Discover how sugar molecules quietly damage your proteins and cells over time — and what you can do to slow down this sneaky aging process.
FDA approval of the first T1D delay drug nearly doubled islet autoantibody testing, but critical gaps remain in screening healthy children.
A new review links feline age-related obesity to SASP-driven chronic inflammation, offering translational insights for human metabolic disease.
The triple agonist retatrutide drives deep metabolic shifts beyond weight loss, improving key biomarkers of cardiovascular and insulin health.
Scientists identify IL-11 as a molecular brake on beige fat thermogenesis, and show blocking it improves metabolism in obese mice.
Diabetes drugs like empagliflozin show surprising anti-aging effects — mimicking caloric restriction and reducing senescent cell burden.
